All In MedTech

Device Trial Radar · NCT02224755

MOMENTUM 3 IDE Clinical Study Protocol

Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol

Last checked: Nov 19, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,028 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,028

Actual

Start

Sep 2, 2014

Primary completion

Sep 28, 2018

Study completion Mar 26, 2019

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
Collaborators
Thoratec Corporation
First posted
Aug 25, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and effectiveness of the HM3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.

Conditions

  • Advanced Refractory Left Ventricular Heart Failure

Interventions

  • HeartMate 3 LVASDevice

    Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure

  • HeartMate II LVASDevice

    Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short Term Primary End PointTime frame: The first 294 randomized Subjects will be followed for 6 months or to outcome (transplant, explant, or death), whichever occurs first.
  2. Long Term Primary End PointTime frame: The first 366 randomized Subjects will be followed for 24 months or to outcome (transplant, explant, or death), whichever occurs first.

Locations

69 sites in 1 country. Site status is shown where the registry gives one.

  • Baptist Health Medical Center - Little Rock

    Little Rock, Arkansas

  • Cedars Sinai Medical Center

    Beverly Hills, California

  • University of California, San Diego

    La Jolla, California

66 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.